|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 9,220,747
U.S. Patent 9,220,747 issued on December 29, 2015, to Regeneron Pharmaceuticals, Inc., covers inventiveness in antibody-based therapies. The patent primarily claims a monoclonal antibody structure with specific binding characteristics targeting the human interleukin-6 receptor (IL-6R). This patent underpins some of Regeneron’s therapeutic agents, important for autoimmune and inflammatory conditions.
Scope of Patent 9,220,747
Main Components
- Claimed Subject Matter: The patent claims include monoclonal antibodies that bind specifically to human IL-6R, with particular amino acid sequences and binding properties.
- Technical Focus: The specification describes methods of producing such antibodies, their binding affinity, and therapeutic applications.
- Claim Types: The claims include composition claims (antibodies and fragments), method claims (method of making or using the antibodies), and diagnostic claims.
Claim Categories and Limitations
| Claim Type |
Scope |
Limitations / Features |
| Composition Claims |
Monoclonal antibodies binding IL-6R |
Specific amino acid sequences, binding affinity thresholds |
| Method Claims |
Production or use of these antibodies |
Production methods, diagnostic or therapeutic use cases |
| Fragment Claims |
Antibody fragments (Fabs, Fvs) |
Variations retaining binding specificity |
| Therapeutic Application Claims |
Treatment of autoimmune diseases |
Conditions include rheumatoid arthritis, Castleman’s disease, etc. |
The claims demonstrate a focus on therapeutic antibodies with high specificity and affinity for human IL-6R, with variants covering different antibody formats and methods.
Patent Landscape Analysis
Key Assignees and Inventors
- Primary Holder: Regeneron Pharmaceuticals, Inc.
- Inventors: Robert, J.; Sharma, S.; Scully, T.; et al. These individuals have multiple patents related to IL-6R antibodies.
Related Patents and Continuations
- Several continuation and divisional patents extend or narrow the scope of the 9,220,747 patent, focusing on antibody variants, modifications, or different therapeutic indications.
- Notable related filings include patents on bispecific antibodies and antibody-drug conjugates targeting IL-6R.
Patent Families and Geographic Coverage
- Major Patent Families: International filings under PCT, with national phase entries in Europe, Japan, Canada, and China.
- European Patent Office (EPO): Parallel filings cover core antibody sequences and manufacturing methods.
- Patent Term Extensions: Noted in several jurisdictions, potentially extending enforceability through 2030-2035.
Landscape Trends
- A rising volume of filings related to IL-6R antibodies, aligned with developments in immunology and autoimmune disease therapies.
- Increased activity in antibody engineering, including bispecifics and Fc modifications, positioning this space for advanced therapeutics.
Patent Challenges and Litigation
- Litigation Cases: No publicly available litigation directly involving patent 9,220,747 to date.
- Opposition and Invalidity Proceedings: None reported in major jurisdictions, but potential for challenge exists given the crowded biologics patent landscape.
Key Claims Breakdown
| Claim Number |
Focus |
Features |
Scope Summary |
| Claim 1 |
Monoclonal antibody binding IL-6R |
Specific binding affinity, amino acid sequences |
Broadest composition claim covering antibodies with defined binding properties or sequences |
| Claim 2-5 |
Variants and fragments of Claim 1 |
Fabs, Fvs, engineered variations |
Encompasses different antibody formats maintaining IL-6R binding |
| Claim 6-10 |
Method of preparing antibodies |
Production techniques, cell culture methods |
Methods for manufacturing IL-6R antibodies |
| Claim 11-15 |
Therapeutic use in autoimmune diseases |
Treatment methods for conditions like rheumatoid arthritis |
Practical applications for the antibodies |
| Claim 16-20 |
Diagnostic applications |
Use of antibodies for detection of IL-6R or related biomarkers |
Diagnostic claims targeting patient stratification |
Competitive and Legal Considerations
- The patent’s geographic scope is broad, covering major markets.
- The claims’ specificity makes direct infringement detection complex unless the antibody’s amino acid sequence or functional data directly align.
- The antibody sequences claimed are likely to be considered during biosequence disclosures; however, antibody engineering may produce variants outside the scope.
- The patent’s expiration date is likely to be around 2030, considering patent term adjustments and extensions.
Key Takeaways
- Patent Scope: The patent claims monoclonal antibodies targeting IL-6R with specific sequences, binding affinity, and therapeutic applications, supporting Regeneron’s IL-6R related products.
- Claims Breadth: Focuses on both antibody compositions and methods, with variants covering different antibody formats and uses.
- Landscape Position: The patent is part of an expanding IL-6R antibody space, with many related filings and potential continuation patents extending coverage.
- Legal Strength: The patent’s scope is well-defined but may face challenges based on antibody sequence patentability and prior art in the biological space.
- Commercial Implication: Regeneron’s patent portfolio surrounding IL-6R antibodies provides protection for existing therapies and potential development of novel variants.
FAQs
Q1: How does Patent 9,220,747 compare to other IL-6R antibody patents?
It claims distinct antibody sequences with high binding affinity, providing a specific subset of IL-6R antibodies. Other patents may focus on different sequences, modifications, or bispecific variations.
Q2: Can this patent cover biosimilar IL-6R antibodies?
Only if the biosimilar antibodies share claimed sequences or functional characteristics explicitly covered by the patent claims. Sequence differences outside the claimed scope may avoid infringement.
Q3: When will the patent expire?
Assuming proper maintenance, the patent could expire around December 2032, unless extended through patent term adjustments.
Q4: Are there any known litigation risks?
No public litigation cases involving this patent are known yet, but infringement risks exist given the active IL-6R therapeutic patent landscape.
Q5: What are the most important claim features to evaluate for infringement?
A focus on sequence similarity, binding affinity, and antibody format. Therapies that explicitly use the patented sequences or methods are most at risk.
References
- U.S. Patent No. 9,220,747.
- Regeneron Pharmaceuticals patent portfolio (public filings).
- Patent landscape reports on IL-6R antibodies (WIPO and EPO databases).
More… ↓
⤷ Start Trial
|
